Copyright © Inderes 2011 - present. All rights reserved.

Optomed

2.88 EUR

+1.05 %

5,645 following
Corporate customer

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+1.05 %
-24.51 %
-23.61 %
-30.10 %
-25.49 %
-32.00 %
-34.77 %
-53.85 %
-37.12 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
61.79M EUR
Turnover
110K EUR
P/E (adj.) (26e)
-17.31
EV/EBIT (adj.) (26e)
-17.05
P/B (26e)
3.02
EV/S (26e)
3.17
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
3.80 EUR
Updated
11.02.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 11.02.2026

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.5
2026

Interim report Q1'26

8.5
2026

General meeting '26

14.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Optomed Q4'25 preview: Fokus på forventninger
Analyst Comment by
Juha Kinnunen

Optomed Q4'25 preview: Fokus på forventninger

Optomed offentliggør sit Q4 regnskab næste tirsdag. Hovedfokus i regnskabet er rettet mod omsætningsvækstprognosen for 2026, som vi forventer vil være i form af "stærk vækst". Vores opmærksomhed i regnskabsmeddelelsen er især rettet mod den kommercielle udvikling af vækstfaktorerne i Udstyr-segmentet, såsom Aurora AEYE-løsningen og Optomed Lumo.

Optomed
Forum discussions
In this piece linked by sheikki five days ago, one of the same authors can be found: Tin Yan Alvin Liu, MD (Johns Hopkins). Mr. Liu seems to really like portable cameras… https://www.aao.org/Assets/61411ee7-929d-4a96-b7d5-f864740f95ff/639051185695430000/february-2026-feature-pd profiles...
23 hours ago
by Mr. Stock
12
Very interesting. Does that mean that the doctor would look at all the images, or that the doctor only looks if the AI finds something? The question used in the study was phrased so that the entire diagnosis would be purely by the AI. But as I understand it, other studies have also...
yesterday
11
I noticed that Optomed has had the same guy as Chairman of the Board for 20 years. It doesn’t really seem normal, or healthy for that matter. The guy is also dependent on the company due to a consultancy relationship and the fees received from it. This is the kind of result you get...
9 hours ago
by Puutaheinää
5
Same thoughts here. If a takeover bid were to come in the near future, I would hope it came from someone other than Topcon. This is because I believe Topcon would also be interested, and we could potentially get a bidding war as a result. I don’t fully understand, and it even raises...
10 hours ago
by Choyoba_Capital
4
I haven’t checked the exact details of that case, but generally, the threshold for relying on AI alone is lower in screenings than in actual disease diagnostics.
yesterday
by Puutaheinää
4
Kulukurssi: Can those of you who believe in the power of new CEOs and/or board members explain to a simple guy how the situation would change after a replacement? I’ve always been of the opinion that it doesn’t matter who sits in the chair, as long as it’s not consumer retail where...
8 hours ago
by Maustaja
3
I guess it doesn’t matter who’s swinging the baton there​ I’m more interested in why the insiders aren’t buying the stock now while it’s “cheap”
9 hours ago
by Uuno
3
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.